Factor XI inhibitors - Rising stars in anti-thrombotic therapy?
Christian H Nolte
https://pubmed.ncbi.nlm.nih.gov/39094433/Actively Recruiting
Led by Anthos Therapeutics, Inc. · Updated on 2026-07-13
2500
Participants Needed
789
Research Sites
N/A
Total Duration
Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.
CONDITIONS
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
A
Anthos Therapeutics a Novartis Company
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Anthos Therapeutics, Inc.
Lead Sponsor
Novartis Pharmaceuticals
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Abelacimab injection | Placebo injection | Guideline-based supportive management |
|---|---|---|---|
| What is it? | Abelacimab is a factor XI inhibitor delivered as an injectable biologic, designed to reduce stroke risk in patients with AF who cannot receive standard oral anticoagulation or LAA closure. | Placebo matching abelacimab was administered as an injection to compare outcomes against the investigational treatment in this high-risk AF population. | Supportive management involves risk factor modification, avoidance of oral anticoagulation when contraindicated, and patient education, in line with major guideline recommendations for patients with AF where anticoagulant therapy or LAA closure are unsuitable. |
| Role in trial | Abelacimab is the investigational treatment tested for its ability to prevent stroke and embolic events in high-risk AF patients unsuitable for oral anticoagulants or LAA closure. | Placebo provides a controlled reference for evaluating safety and efficacy outcomes against abelacimab. | Guidelines define supportive care and risk factor modification as the default approach in patients unsuitable for oral anticoagulants or device closure. |
| Primary use | Investigational stroke prevention for AF patients at high risk who cannot receive standard oral anticoagulants or LAA closure. | Control arm for comparative evaluation of risk and benefit against abelacimab in stroke prevention. | Prevention and management of risk factors, symptom control, and education in high-risk AF patients unable to use oral anticoagulants or LAA closure. |
| How is it given or performed? | Abelacimab is administered as a protocol-based injection, with dosing specified in the trial protocol. Patients receive regular injections according to a study schedule. | Placebo injections are provided at the same schedule and appearance as abelacimab to maintain blinding. | Supportive management involves routine assessment, risk factor counseling, optimization of comorbidities, and regular follow-up; no injectable medication or device is used. |
| Evidence status | Abelacimab is undergoing phase 3 evaluation for stroke prevention. Previous evidence suggests factor XI inhibitors may reduce thromboembolism risk with fewer bleeding complications than traditional anticoagulants, but this trial will provide results specific to high-risk AF patients. | Placebo-controlled research allows for clear comparison but provides no active stroke prevention benefit, as placebo itself offers no therapeutic effect. | Supportive management focuses on risk reduction and symptom control; it does not actively prevent stroke or thromboembolism but supports guideline-recommended care in patients unsuitable for anticoagulants or devices. |
| Important limitations | Results for abelacimab in this population are not yet available; safety and efficacy must be confirmed in ongoing research. Administration is by injection, which may affect patient convenience. | Placebo offers no active protection against stroke or bleeding and cannot be used outside research. | Supportive management provides symptom control and risk factor reduction only, with stroke risk remaining elevated for patients unable to receive anticoagulants or device based on guidelines. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 60 days
Participants are screened for eligibility to participate in the trial.
Duration - Event-driven until at least 111 patients experience a primary endpoint event (up to 30 months)
Participants receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once monthly.
Monthly visits
Duration - 30 days for follow-up or longer if in extension
Participants have an end-of-treatment visit followed by a 30-day safety follow-up or may join an optional open-label extension to receive abelacimab if eligible and approved.
1 visit for end of treatment and 1 follow-up visit
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Christian H Nolte
https://pubmed.ncbi.nlm.nih.gov/39094433/Anthos Therapeutics, Inc.
Lead Sponsor
Novartis Pharmaceuticals
Collaborating Sponsor